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Testicular  androgens  suppress  the  synthesis  and se- 
cretion of the  pituitary  gonadotropins,  in  particular, 
luteinizing  hormone.  This  suppressive  effect  includes 
transcription of both the common a subunit  gene  and 
the unique /3 subunit genes. Herein, we demonstrate 
that 1500 base pairs (bp) of proximal  5”flanking  re- 
gion derived from the human a subunit gene and a 
shorter  315-bp  segment of the bovine a subunit  gene 
confer negative regulation by androgen to the gene 
encoding  bacterial  chloramphenicol  acetyltransferase 
in  transgenic mice. Cotransfection assays with  human 
androgen receptor indicated that the 1500-bp pro- 
moter  region of the  human a subunit  gene  also  confers 
androgen regulation (transcriptional suppression) to 
reporter genes in both pituitary and placental cell 
lines. This raises the possibility of a role for DNA 
binding in  suppression of a subunit  transcription by 
activated  androgen  receptor.  Consistent  with  this pos- 
sibility, we have used a gel-mobility shift assay to 
detect  several high affinity  binding  sites  for  androgen 
receptor located in  the  proximal  promoter of the  hu- 
man a subunit gene. The  strongest  androgen  receptor 
binding  site is located at  approximately -101 in  the 
proximal 5”flanking region. This steroid receptor 
binding site overlaps  another  binding  site  that  defines 
one of several contiguous cis-acting regulatory ele- 
ments  required  for  basal  transcriptional  activity. 
Thus,  binding of activated  androgen  receptor  to  this 
region may block the binding of a requisite trans- 
acting  factor  and  lead  to  an  attenuation  in  transcrip- 
tion. We conclude that  this  interaction,  which  occurs 
directly at  the level of the  pituitary,  represents  one of 
several physiological avenues through which andro- 
gens  regulate  gonadotropin  gene  expression. 
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The  gonadotropins  luteinizing  hormone  (LH)’  and follicle 
stimulating  hormone (FSH) are  members of the glycoprotein 
hormone family and  as  such  are  heterodimers composed of an 
identical a subunit  and  distinct @ subunits (Fiddes and  Tal- 
madge, 1984). The common a subunit and each of the p 
subunits are encoded by unique single copy genes that  are 
expressed in specific cell types  (gonadotropes) of the  anterior 
pituitary gland (Fiddes and Talmadge, 1984; Gharib et al., 
1990). 
Synthesis and secretion of LH and FSH are exquisitely 
regulated  via  negative  feedback by gonadal  estrogen and  an- 
drogen acting  either directly at  the  pituitary  or at the hypo- 
thalamus  to  affect  secretion of gonadotropin releasing hor- 
mone  or  GnRH  (Brinkley, 1981; Desjardins, 1981; Gharib et 
al., 1990). Accordingly, castration typically results  in  an ele- 
vation of both  pituitary  and  circulating  concentrations of LH 
and  FSH  that  can be attenuated by replacement with either 
estrogen or androgen. Negative feedback effects of gonadal 
steroids include transcription of both the common a and 
unique @ subunit genes (Gharib et al., 1990). Consequently, 
changes in synthesis and secretion of intact heterodimers 
result from coordinated and regulated expression of both 
subunits even though  the molecular mechanisms  that  control 
expression may be distinct  for  the  different genes. 
Due  to  the lack of pituitary cell lines that  synthesize  and 
secrete biologically active LH or FSH, we used transgenic 
mice to  characterize  the  proximal  promoter-regulatory regions 
of the human and bovine glycoprotein hormone a subunit 
genes. Previously, we have demonstrated  that 1500’ bp of 5’- 
flanking region derived  from the gene encoding the  human a 
subunit  is sufficient to confer both  estrogen  and  GnRH reg- 
ulation to a heterologous reporter gene (Keri et al., 1991; 
Hamernik et al., 1992). Moreover, this promoter fragment 
targets  expression of several different  reporter genes to  the 
pituitary  and, specifically, to  gonadotropes  within  the  pitui- 
tary (Hamernik et al., 1992). Similar results were obtained 
The abbreviations used are: LH, luteinizing hormone; FSH, fol- 
AR, androgen receptor; ARE, androgen response element; GnRH, 
licle stimulating hormone; bp, base pair(s); ER, estrogen receptor; 
gonadotropin releasing hormone; GR, glucocorticoid receptor; GRE, 
glucocorticoid response element; CRE, CAMP response element; 
CREB, CRE-binding protein; JRE, junctional regulatory element; 
rAR-DBD, rat AR DNA binding domain; CAT, chloramphenicol 
acetyltransferase; CMV, cytomegalovirus; MMTV, mouse mammary 
tumor virus; T, testosterone; E, estradiol-17S; DHT,  5a-dihydrotes- 
tosterone. 
In most of our previous publications, this fragment has been 
referred to as a 1500-bp fragment. Preliminary sequence analysis 
indicates that the correct size is 1635 bp. For convenience and 
continuity, we will continue to refer to this region as a 1500-bp 
fragment (estimated by agarose gel electrophoresis). 
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with a shorter fragment of the promoter from the bovine a 
subunit gene (315 bp of proximal 5'-flanking region) (Kendall 
et al., 1991; Hamernik et al., 1992), suggesting that  the  pro- 
moters of both  the  human  and bovine a subunit genes share 
highly conserved mechanisms regarding gonadotrope-specific 
expression and regulation by estradiol and  GnRH (Keri et al., 
1991; Hamernik et al., 1992). 
The negative effect of estrogen on transcriptional activity 
of the human a subunit promoter is unusual as  this region 
lacks a high affinity binding site for estrogen receptor (ER) 
(Keri et al., 1991). In addition,  activated ER failed to suppress 
expression of a chimeric human  aCAT vector in  cotransfec- 
tion studies (Keri et al., 1991). Thus, estrogen appears to 
regulate expression of the  human a subunit  promoter  through 
an indirect mechanism that remains undefined but may in- 
volve both  the hypothalamus  (inhibition of GnRH secretion) 
and pituitary  (interference  with some component of the 
GnRH signal transduction  pathway). 
A significant component of the negative feedback by andro- 
gen  may  be due to inhibition of GnRH synthesis and secretion 
(Desjardins, 1981;  Crowley et al., 1985; Tilbrook et al., 1991). 
Several lines of evidence, however, prompted us  to  further 
explore the potential for a  direct effect of androgen on  expres- 
sion of the a subunit gene. First, like ER, androgen receptor 
(AR) is expressed in the  anterior  pituitary gland (Naess et al., 
1975; Thieulant  and Pelletier, 1979; Schanbacher et al., 1984; 
Bonsall et al., 1985). Second, there have been several reports 
indicating that androgen can suppress levels of a subunit 
mRNA in  pituitary cells devoid of hypothalamic input (Wier- 
man et al., 1988; Ahlquist et al., 1990; Paul et al., 1990; 
Wierman and Wang, 1990). Third, Akerblom et al. (1988) 
suggested that glucocorticoid can inhibit expression of the 
human a subunit gene by a mechanism involving binding of 
activated glucocorticoid receptor (GR) to several sites that 
either overlap or are in close proximity to two tandemly 
repeated CAMP response elements (CRE) residing in the 
proximal promoter. More recently, Chatterjee et al. (1991) 
suggested that mutually exclusive binding of GR and  CREB 
represents an unlikely mechanism for glucocorticoid repres- 
sion of a subunit gene expression. Rather, these authors 
implicate a squelching mechanism whereby GR directly binds 
CREB or binds to a shared class of transactivating proteins. 
An essential feature of both reports, however, is a GR-me- 
diated  interference of CREB transactivation. In light of these 
conflicting data  and  the well established convergence of DNA 
binding sites for AR and GR (Cato et al., 1987; Quarmby et 
al., 1990; Tan et al., 1992), we were intrigued with the possi- 
bility that  the  tandem  CREs of the human a subunit gene 
might be physiological targets of  AR. 
Accordingly, we have extended the use of our transgenic 
paradigm and incorporated both cotransfection and DNA- 
binding studies to determine whether androgen suppresses 
transcription of the human a subunit gene through  a  direct 
mechanism. Herein we report  a  surprising finding. Androgens 
suppress activity of the  human a subunit promoter  in trans- 
genic mice. Moreover, the proximal a subunit promoter  con- 
tains a high affinity binding site for AR. However, rather 
than co-map with the CREs, as did GR (Akerblom et al., 
1988), the AR binding site maps to a  different region posi- 
tioned between the downstream  CRE and  the CCAAT box 
and referred to as a junctional regulatory element (JRE) 
(Andersen et al., 1990; Kennedy et al., 1990). Collectively, our 
results suggest that direct binding of activated AR to  the  JRE 
may account, at least  partially, for physiological regulation of 
expression of the  human a subunit promoter by androgen. 
EXPERIMENTAL  PROCEDURES 
Materials-Acetyl  coenzyme A, 5a-dihydrotestosterone, and  estra- 
diol-178 were obtained from Sigma. Radionuclides were obtained 
from Du Pont-New England Nuclear. DNA modifying enzymes and 
restriction enzymes were obtained from either Boehringer Mannheim 
or GIBCO/BRL. Constant time release pellets containing either 
testosterone (T), 5a-dihydrotestosterone (DHT), or estradiol-17P (E) 
were obtained from Innovative Research of America (Toledo, OH). 
The plasmid pMMTV-CAT was a gift from Dr. Steve Nordeen. 
Purified AR and Antibody-Bacterially expressed and purified rat 
AR DNA binding domain (amino acid residues 460-7041, henceforth 
referred to as rAR-DBD, was prepared as previously described 
(Quarmby et al., 1990). The antibody (AR-52) used in the gel-mobility 
shift assays is directed against an epitope (amino acid residues 527- 
541) that maps to  the  rat AR DNA binding domain (Quarmby et al., 
1990). 
Animals-Transgenic mice harbored one of two different CAT 
chimeric genes. Transcription of the CAT gene  was directed by either 
1500  bp of 5"flanking sequence from the human a subunit gene or 
315  bp of the bovine counterpart.  These two lines of  mice (HaCAT 
or BaCAT) were produced and characterized previously (Bokar  et al., 
1989). Both lines have been propagated in our laboratory; the animals 
used in the present experiments were at least 10 generations from 
founder animals and harbored the transgenes at single integration 
sites. 
Castration and Steroid Replacement Paradigms-Castrations were 
performed under general anesthesia using a combination of ketamine 
and acepromazine (Hamernik  et al., 1992). At the time of castration, 
a constant release pellet containing  either T (5 mg/pellet), DHT  (5 
mg/pellet), E (0.25 mg/pellet), or placebo was implanted subcutane- 
ously. At  2 weeks post-castration, animals were euthanized and 
pituitaries,  brains, and livers were harvested for assay of CAT activity 
(Bokar et al., 1989; Keri et al., 1991). Trunk blood samples were 
collected for assay of serum hormone concentrations. 
Assays-Lysates  were prepared from tissues and CAT activity was 
assayed as previously described (Bokar  et al., 1989; Keri et al., 1991). 
Nonspecific CAT activity or background was determined by including 
homologous tissues from non-transgenic mice in each assay. Serum 
concentrations of E and T were measured using Pantex (Santa 
Monica, CA) radioimmunoassay kits validated in our lab for use with 
mouse serum (Keri et al., 1991). Serum concentrations of LH and 
DHT were measured using validated radioimmunoassay procedures 
(Hamernik  et al., 1992). 
Plasmids-Plasmids pHo((-1500)CAT, pRSVCAT, and pSVOCAT 
have been described by Bokar et al.  (1988, 1989). Estrogen receptor 
expression vector (pHEO; henceforth referred to as hER) and 
pSVlvERECAT  (henceforth referred to as pVERECAT) have been 
described by Keri et al. (1991). Human AR expression vector 
(pCMVhAR) consists of the full-length AR cDNA fused to the 
cytomegalovirus promoter (Quarmby et al., 1990). Plasmid pMMTV- 
CAT consists of a 2.9-kilobase pair  BamHI fragment containing the 
MMTV long terminal repeat fused to CAT (Darbre  et al., 1986). 
Cell Lines and Transfections-For transient  transfection studies, 
aT3 cells (Windle et al., 1990) were plated in Dulbecco's modified 
Eagle's medium with 5% fetal bovine serum, 5% horse serum and 
antibiotics a t  a density of 2 X lo6 cells/lOO-mm plate on the day prior 
to transfection. Culture conditions for BeWo cells have been de- 
scribed previously (Silver et al., 1987). Cells were transfected using 
the indicated amounts of vectors by calcium-phosphate coprecipita- 
tion  (Gorman  et  al., 1982) and were harvested at 3 days post-trans- 
fection. On the day after  transfection, cells were cultured in complete 
medium containing  either M DHT, M E in ethanol, or a 
similar amount of ethanol without steroid. Cells were replenished 
with fresh media on the day prior to harvesting. After harvesting, 
cellular lysates were prepared and assayed for CAT activity as de- 
scribed (Silver et al., 1987; Bokar et al., 1989). Initial  transfections 
were carried out using media free of phenol red however, later 
experiments indicated no difference in either the presence or absence 
of phenol red. Thus,  data from both treatment groups were pooled 
for analyses. Charcoal-stripped serum was  used in all transfections. 
In each cotransfection with pCMVhAR, a positive control for andro- 
gen response (pMMTV-CAT) and a negative control (pRSVCAT) for 
promoter specificity was included. 
Gel-mobility Shift Assays-End-labeled  DNA fragments were  used 
as probes in gel-mobility shift assays using purified rAR-DBD. The 
procedural details of the assay are as described by Tan et al.  (1992). 
Briefly, rAR-DBD (500 pg) was preincubated at 4 "C for 15 min in 
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binding buffer (10 mM Tris-HC1, pH 7.5, 25 mM KC1, 10% glycerol, 
0.1 mM EDTA, 1 mM dithiothreitol) with 2 pg  of poly(d1-dC) and 100 
pg of bovine serum albumin. Approximately 10,000 cpm (0.1-0.5 ng) 
of probe was added to the reaction, and binding was allowed to 
proceed for 15 min at room temperature. Subsequently, the anti-AR- 
DBD antibody, AR-52,  was added to  the appropriate binding reactions 
and incubations were continued for an additional 15 min at room 
temperature. Following an additional incubation at 4 "C for 30 min, 
2 pl of 0.2% bromphenol blue was added to each sample and samples 
were subjected to electrophoresis in 4% polyacrylamide gels (0.5 X 
TBE)  at 4 "C for 4-5 h. Gels were dried and exposed to Kodak X- 
Omat film at -70 "C. 
Competition gel-mobility shift assays were performed with four 








I JK 5'-TCATTGGATGGAATTTCCTGTTGATCCCAG-3' 
(position -go/-60) 
A 215-bp fragment of the a subunit  promoter corresponding to bases 
-170 to +45 was also end-labeled by a fill-in reaction with the Klenow 
fragment of DNA polymerase I; 21 fmol of probe were used in each 
assay. Competitors were added immediately preceding the addition 
of probe in amounts corresponding to 12, 50, and 100 times the 
amount of probe in each reaction. The reactions remained on ice for 
10 min. Antibody (AR-52) was added, and  the reactions were further 
incubated at  room temperature for 15 min followed by a 5-min 
incubation on ice  before loading onto a 5% polyacrylamide gel. 
RESULTS 
Castration Leads to a Pituitary-specific Increase in aCAT 
Expression in Transgenic Mice-Adult male transgenic mice 
harboring either the Ha(-1500/+45)CAT or Ba(-315/ 
+45)CAT transgenes were castrated. At 2 weeks post-castra- 
tion,  pituitaries,  brains  (frontal  cortex),  and livers were har- 
vested and assayed for CAT activity (Bokar et al., 1989; Keri 
et al., 1991). 
Pituitary CAT activity was significantly higher in castrated 
transgenic mice as compared to  intact controls (Fig. 1). Con- 
sistent with localization of the transgene to gonadotropes 
(Kendall et al., 1991; Hamernik et al., 1992), the increase in 
CAT expression was pituitary-specific. The CAT activity 
observed in the brain of the  HaCAT transgenic mice agrees 
with our previous studies of this line of mice (Bokar et al., 
1989; Keri et al., 1991) and may reflect colocalization of 
transgene activity with previously observed patterns of extra- 
pituitary  sites of expression of thyroid  stimulating hormone 
and  LH  (Hojvat  et al., 1982; Hostetler et al., 1987). 
Based on these results we concluded that 1500 bp of prox- 
imal 5"flanking region from the Ha subunit gene, or 315 bp 
of the bovine counterpart, is sufficient to confer responsive- 
ness to negative feedback effects by testicular hormones. The 
predominant gonadal steroids secreted by the mouse testis 
are T and DHT, with minimal to undetectable levels of E 
(Desjardins and Chubb, 1983). We therefore tested whether 
replacement with either androgen or estrogen would act  to 
attenuate  the post-castrational rise in pituitary CAT activity. 
Androgen and Estrogen Suppress  the  Post-castrational Rise 
in Pituitary CATActiuity in Either  HaCAT or BaCAT  Trans- 
genic  Mice-Adult,  male transgenic mice  were castrated and 
fitted with subcutaneous, constant release pellets containing 
either T, DHT, or E. Control animals were castrated and 
received pellets containing inert carrier. At  2 weeks post- 
Pit  Brain  Liver  Pit  Brain  Liver 
FIG. 1. Castration results in a pituitary-specific increase in 
human and bovine &AT expression in transgenic mice. Adult 
male transgenic mice harboring either Ha(-1500/+45)CAT (n = 7) 
or Ba(-315/+45)CAT (n = 6) were castrated. At 2 weeks post- 
castration, pituitaries, brains, and livers were harvested from the 
castrates (shaded burs) and  intact controls (open burs) and assayed 
for CAT activity. The cartoon at  the top of the figure depicts the 
major regulatory regions of the human and bovine a subunit pro- 
moters (URE, upstream regulatory element; CRE, CAMP response 
element)  (Bokar et ul., 1989; Silver et ul., 1987; Delegeane et uL, 1987). 
Aside from length, a primary difference between the human and 
bovine a transgenes is the absence of a functional CRE in the bovine 
a promoter. 
castration, tissues were analyzed for CAT activity as above. 
Trunk blood  was collected and serum was assayed for concen- 
trations of T, DHT, E, and LH. 
The  constant release pellets resulted in physiological con- 
centrations of T and  DHT (T = 7.8 f 1.8 ng/ml; DHT = 1.4 
f 0.8 ng/ml) (Desjardins and Chubb, 1983) in serum. Serum 
concentrations of E averaged 323 f 62 pg/ml. To further 
verify that biologically active concentrations of androgen were 
achieved, we also isolated seminal vesicles from each mouse. 
Consistent with the physiological concentrations of androgen 
assayed in  serum, the paired weight of seminal vesicles  was 
higher in T-implanted mice (178 f 13 mg) and DHT-im- 
planted mice (166 f 7 mg) than either controls (41 f 2 mg) 
or  E-implanted mice  (59 f 3 mg). 
The CAT activity assayed in  pituitaries of either the 
HaCAT  or  BaCAT transgenic mice receiving T implants was 
significantly lower than  that measured in  pituitaries of cas- 
trate controls (Fig. 2, A and B ) .  Thus, T replacement was 
effective in suppressing the post-castration increase in expres- 
sion of both the  Ha and Ba transgenes. To provide a phys- 
iological correlate for pituitary CAT activity, we also meas- 
ured serum concentrations of LH. Consistent with the  atten- 
uation  in  pituitary CAT activity, treatment with T resulted 
in severely suppressed serum concentrations of LH. Thus, 
1500 or 315 bp of proximal 5'-flanking region derived from 
either the Ha or Ba subunit gene is sufficient to confer 
negative regulation by T in transgenic mice. 
The suppressive effects of DHT on transgene expression 
were not  as pronounced as T. In light of the relative instability 
of DHT  in blood, one explanation for the reduced suppression 
by DHT is simply that  the dose of DHT was only minimally 
effective; however, serum concentrations of DHT were in a 
physiological range and sufficient to maintain seminal vesicle 
weight. Another explanation is that suppression of a trans- 
gene expression in T-implanted mice was a consequence of 
both  a  direct effect of androgen and  an indirect effect that 
occurs after  either  target  site  or peripheral aromatization to 
estrogen. This would explain the partial suppression of pitui- 
tary CAT activity that occurred when animals were treated 
with either DHT  (a non-aromatizable androgen) or E alone. 
Nevertheless, replacement with DHT did result in signifi- 
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Castrate T DHT E 
Castrate T DHT E 
FIG. 2. Androgen and estrogen suppress the post-castra- 
of LH in either  the Ha(-1500/+45)CAT (panel A )  or 
tional  rise in pituitary CAT activity  and  serum  concentrations 
Ba(-316/+4S)CAT (panel B )  transgenic mice. Adult male, 
transgenic mice were castrated and  fitted with constant release pellets 
containing either testosterone (T), 5a-dihydrotestosterone (DHT), 
or estradiol-17P ( E ) .  Control animals were castrated and received 
pellets containing inert carrier. Each treatment group contained a 
minimum of 7 animals. At 2 weeks post-castration, pituitaries were 
harvested and analyzed for CAT activity. Trunk blood was collected, 
and serum was assayed for LH concentrations. Vertical burs with 
different lettered superscripts represent statistical differences in CAT 
activity ( p  < 0.05). Similarly, vertical bars with different Greek 
symbols (a, 0, y) represent significantly different levels of serum LH 
( p  C 0.05). 
cantly suppressed pituitary expression of the  BaCAT  trans- 
gene. Thus, androgenic regulation of the a subunit gene in 
transgenic mice is demonstrable  in two distinct lines of mice 
harboring a subunit  transgenes from different species. 
In general, effects of androgen replacement on serum con- 
centrations of LH were similar to those for a transgene 
expression. That is, T replacement resulted in severely sup- 
pressed serum concentrations of LH in both lines of trans- 
genic mice as compared to  castrate controls. The effects of 
DHT were less pronounced and resulted in LH levels that 
were intermediate between those measured for castrate con- 
trols or mice implanted with either T or E. 
In contrast to the effects of E in partially suppressing 
expression of the HaCAT and BaCAT transgenes, serum 
concentrations of LH in E-treated mice were not different 
from animals  treated with T. As LH is composed of both an 
a and  a @ subunit, it may be that expression of LHP is more 
sensitive than  the (Y subunit to negative feedback effects of E. 
From these experiments, we conclude that sequences con- 
tained within the proximal promoter regions of the  Ha  and 
Ba subunit genes can confer both androgenic and estrogenic 
regulation on a bacterial reporter gene in male, transgenic 
mice. 
Co-expression of Human AR Suppresses Ha(-l5OO)CAT 
Expression in a Steroid-dependent Manner-Negative tran- 
scriptional regulation of the  Ha subunit promoter by  AR was 
studied by cotransfecting a human AR expression vector 
(pCMVhAR) with pHa(-1500)CAT into two cell lines known 
to express the a subunit gene -aT3 cells, a mouse cell line of 
gonadotrope lineage (Windle et al., 1990) and BeWo  cells, a 
human choriocarcinoma cell line (Bokar  et al., 1989). Data in 
the cotransfection experiments  are presented as relative CAT 
activity. This was calculated from the activity of each treat- 
ment group (kAR,  kDHT)  as percent of activity from the 
control plates. Controls are defined as activity of the test 
vector pHa(-1500)CAT in cells lacking treatment with both 
exogenous AR (transfection)  and steroid. The co-expression 
studies were confined to  the  Ha subunit promoter for two 
important reasons. First,  consistent with its normal pattern 
of expression, the  Ba subunit promoter is inactive in BeWo 
cells (Bokar et al., 1989). Second, although somewhat surpris- 
ing in light of the robust expression of Ba(-315)CAT in 
transgenic mice, expression of this same construct is  10-30- 
fold  lower than Ha(-1500)CAT in aT3 cells (data  not shown), 
thus compromising any functional analysis of negative regu- 
latory elements. 
In aT3 cells, there was no effect of DHT at 50 ng of 
cotransfected AR (Fig. 3). At 0.5, 1.0, and 5.0 pg  of AR, 
treatment of cells with DHT resulted in a significant reduc- 
tion in expression of pHa(-1500)CAT. In addition to steroid- 
dependent suppression, cotransfection with 5.0 pg of 
pCMVhAR also resulted in steroid-independent suppression 
of CAT activity. It may  be that  this reflects steroid independ- 
ent binding of  AR to DNA due to high  levels of expression of 
AR. Alternatively, the constitutively active CMV promoter 
may compete for binding to limiting trans-acting factors. In 
fact, a significant suppression of CAT activity was observed 
in both BeWo cells and aT3 cells when 10 pg  of 
Ha(-1500)CAT was cotransfected with 5.0 pg of a CMV- 
growth hormone reporter vector (data not shown). Thus, 
“steroid-independent’’ suppression by pCMVhAR probably 
reflects a combination of high levels of expression of  AR and 
competition for trans-acting factors by the CMV promoter. 
Regardless of the exact mechanism, both steroid-dependent 
0 - DHT 
D + DHT :! 
ug hAR: 0 0.05 0.5 1 .o 5.0 
FIG. 3. Co-expression of human AR in aT3 pituitary cells 
suppresses Ha(-1500/+45)CAT expression in a steroid-de- 
pendent manner. Ten pg of pHa(-1500/+45)CAT were transiently 
cotransfected with the indicated amounts of human androgen expres- 
sion vector ( A R )  into aT3 cells. On the day after transfection, cells 
were treated with medium containing M DHT in ethanol or 
ethanol alone. Cells were harvested approximately 48 h later, and 
CAT assays were performed. Relative CAT activity  is the percentage 
of CAT activity measured in lysates from cells transfected with 10 pg 
of pHa(-1500/+45)CAT in the absence of DHT and AR. Values 
represent the mean .+ S.E. of triplicate plates in 4 independent 
transfections. CAT activities for pMMTV-CAT and pRSV-CAT co- 
transfected with 5.0 pg of pCMVhAR  are expressed as the percentage 
of CAT activity measured for vector alone (see inset). 
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and steroid-independent suppression of H~(-15OO)CAT ac- 
tivity  appear to be promoter-specific, because neither effect 
was observed when AR was cotransfected with pRSVCAT. A 
significant, steroid-dependent induction of CAT activity was 
observed when  5.0 pg  of  AR was co-expressed with pMMTV- 
CAT, consistent with the presence of multiple GRE/ARE 
sequences within the long terminal repeat of the MMTV 
promoter (Cato et al., 1987; Otten et al., 1988). 
The ability of AR to inhibit expression of Ha was also 
demonstrable in BeWo cells. As in aT3 cells, there was no 
effect of DHT on expression of Ha("1500)CAT at 50 ng of 
cotransfected A R  at 0.5 pg of AR, the inclusion of DHT  in 
the media led to a  steroid-dependent reduction in CAT activ- 
ity (data  not shown). 
In contrast  to AR, we were not  able to demonstrate  any 
steroid-dependent suppression of Ha(-1500)CAT expression 
when aT3 cells were cotransfected with a  human ER expres- 
sion vector (Fig. 4). This  further confirms our previous obser- 
vations  in BeWo and MCF-7 (a  human  breast carcinoma cell 
line) cells that estrogen, unlike androgen, cannot directly 
regulate expression of the  human a subunit gene (Keri et at., 
1991). 
Collectively, these data suggest that AR can negatively 
regulate activity of the Ha subunit promoter in a steroid- 
dependent, promoter-specific manner. We next asked whether 
AR is capable of binding directly to sequences located within 
the proximal 1500 bp of 5"flanking region of the Hcu subunit 
gene. 
AR 3inds to an Element Residing within the Promoter- 
regulatory  Region of the Human a Subunit Gene-To inves- 
tigate binding of  AR to  the  Ha subunit  promoter, we prepared 
a series of restriction fragments spanning 1500 bp of the 
proximal 5"flanking region (Fig. 5A, upper panel). Each 
fragment was end-labeled and used as a probe in gel-mobility 
shift assays using bacterially expressed and purified DNA 
binding domain of the  rat AR (rAR-DBD). AR bound to probe 
Hg hER: 0 1 .o 5.0 
FIG. 4. Estradiol fails to suppress  expression  of pHa(1500/ 
+46)CAT transiently  cotransfected with human ER expres- 
sion vector in aT3 pituitary cells. Ten pg of pHn(-1500/ 
+45)CAT was transiently cotransfected with the indicated amounts 
of human ER expression vector (hER) into aT3 cells. On the day 
after  transfection, cells were treated with medium containing  either 
lo-' M estradiol-170 in  ethanol  or  ethanol alone. Cells were harvested 
approximately 48 h  later, and CAT assays were performed. Relative 
CAT activity is the percentage of CAT activity measured in lysates 
from cells transfected with 10 pg of pHff ( - l5~/~45)CAT in the 
absence of estradiol and hER. Values represent the mean 3z S.E. of 
pVERE-CAT and pRSV-CAT cotransfected with 5.0 pg  of hER  are 
triplicate  plates  in 2 independent  transfections, CAT activities for 
expressed as the percentage of CAT activity measured for vector 
alone (see inset). The pVERE-CAT plasmid contains the vitellogenin 
ERE positioned upstream of the SV40 promoter  without its enhancer 
(Keri et d., 1991). 
was identified by including a specific antibody to  the rAR 
DNA binding domain (AR-52) (Tan et at., 1992). Inclusion of 
both rAR-DBD and AR-52 further  retards the migration of 
the probe through the gel  if a binding site for AR is present 
within the probe sequence (illustrated in Fig. 5A, lowerpanel). 
The results of a gel-mobility assay using eight restriction 
fragments spanning 1500 bp of Ha 5"flanking region are 
shown in  Fig. 5B. Also included in  the assay was a fragment 
containing  a previously defined ARE derived from the andro- 
gen-responsive C3 gene (Tan et al., 1992). An antibody- 
dependent  band with retarded migration was readily detected 
when the C3 ARE fragment was incubated with rAR-DBD 
and AR-52 (Fig. 5B, lane 3) .  Likewise, two fragments from 
the Ha subunit  promoter  appeared to bind AR. Fragment 2, 
located between -1100 and -850, probably represents  a weak 
interaction  as judged  by the  faint band (lune 18). In  contrast, 
fragment 4, located between -486 and +45, appears to possess 
the highest intrinsic capacity to bind AR based on the  inten- 
sity of the antibody-dependent band (lane 12). In fact, when 
fragment 4 was cleaved with SauI (see Fig.  5A), a pronounced 
"super-shifted" band was evident for fragment 4B (-170/+45; 
lane 6 ) ,  whereas no binding site was detected  for  fragment 4A 
(-486/-170; lane 9). Collectively, these  data suggest that  the 
binding of AR to fragment 4 can be fully accounted for by 
sequences located within the proximal 170 bp of Ha 5'- 
flanking region. 
Akerblom et al. (1988) suggested that GR is capable of 
binding to three  different regions within 170 bp of proximal 
5"flanking region of the human a subunit gene. At least one 
of these sites mapped to a region overlapping one of two 
tandemly repeated 18-bp CRE located between -146 and 
-110. To determine if  AR might also interact with sequences 
spanning one or both of the CRE, we conducted the gel- 
mobility shift assay using -170-bp human a fragments with 
either one or both of the CRE deleted (ha-A18 and - A B ,  
respectively). Surprisingly, the ability of these  fragments to 
bind AR was not significantly affected despite the absence of 
the CRE  (data  not shown). To  further explore the requirement 
for a functional CRE  in AR binding, we tested the proximal 
promoter (-315/+45) of the  Ba subunit gene that lacks a 
functional  CRE  (Bokar et at., 1989). This region interacted 
with AR but with an  apparent lower affinity than  the homol- 
ogous  region  from the Ha subunit  promoter  (data  not shown). 
Significant sequence differences in  the suspected AR binding 
region probably account for the differences in binding affinity 
noted for the human and bovine a subunit promoters (see 
Fig. 8). Thus,  these  data suggest that  the interaction of AR 
with the a subunit promoter does not require sequences 
contained within tandemly repeated or single CREs. 
To better define the sequences required for binding of AR, 
we further digested the Ha -170/+45 fragment (4B) with 
RsaI (which cleaves at position -99; see Fig. 5A) ,  end-labeled 
each fragment, and subjected each to gel-mobility shift assay. 
Neither subfragment exhibited  binding to rAR-DBD suggest- 
ing that digesting with RsaI effectively disrupted the AR 
binding site (Fig. 6). Curiously, the RsaI site is contained 
within a region referred to as  the junctional regulatory ele- 
ment (JRE) previously implicated as  important for expression 
of human CY subunit gene (Andersen et ai., 19901. 
If the  JRE does represent the critical binding site  for AR, 
then  this element (-120/-90) should be capable of displacing 
binding of AR to  its larger parent radiolabeled fragment of 
the human a promoter, i.e. fragment 4B (-170/+45). This 
possibility was tested directly by oligonucleotide competition 
with four different oligonucleotides corresponding to  se- 
quences near the Rsd  site. Competitions were performed with 
A 
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FIG. 5. A high affinity binding site for AR resides within the proximal 170 bp of the human Q subunit gene promoter. 
Restriction fragments were prepared from approximately 1500 bp of proximal 5”flanking region of the  human a subunit gene (panel A ). The 
inset to panel A shows an expected antibody-dependent  shift  (super-shift  or SS) .  Also shown  is the  unshifted probe (P) and  an  antibody- 
independent  shift ( S ) .  Fragments were end-labeled  with ‘*P and used as probes in a  gel-mobility/super shift assay (panel B) .  Each  fragment 
is represented in the mobility shift  assay by three lanes; -/- = probe  alone; -/+ = probe + rat AR DNA-binding  domain (rAR-DBD); +/+ 
= probe + rAR-DBD + anti-rAR-DBD (AR-52).  C3-ARE is an  authentic androgen-responsive element derived from the C3 gene (Tan et al., 
1992). Asterisks indicate specific AR-DNA  complexes as identified by their  altered migration  relative to binding  assays carried  out in the 
absence of antibody. 
sequences representing either  the  tandem  CRE  (a36, -146/ 
-111) (Bokar et al., 1988), the  JRE  (FGH, -120/-90) (An- 
dersen et al., 1990), the CCAAT box (GHI, -110/-80) (Ken- 
nedy et al., 1990), or a  nonfunctional element  (IJK, -go/-60) 
(Kennedy et al., 1990). Consistent with AR binding specifi- 
cally to  the  JRE region of the  human a promoter, only the 
-120/-90 (FGH) fragment was capable of displacing  binding 
of AR to  the larger radioactive probe (fragment 4B), even 
when the  other competitors were used a t  100-fold excess (Fig. 
7). Collectively, these results indicate that the JRE may 
represent  a physiological target for binding of activated AR 
and suggest a mechanism for transcriptional attenuation 
whereby binding of  AR to  the  JRE would prevent binding of 
another factor required for full transcriptional activity. 
DISCUSSION 
Hormonal regulation of gonadotropin synthesis  and secre- 
tion is extremely complex involving, at the minimum, hy- 
pothalamic input of GnRH  and gonadal input of steroids and 
regulatory  peptides  (Brinkley, 1981; Desjardins, 1981; Gharib 
et al., 1990). The effects of gonadal steroids can occur both a t  
the level of the hypothalamus to affect the synthesis and 
secretion of GnRH  and  at  the level of the  anterior  pituitary 
(Crowley et al., 1985; Gharib et al., 1990). Finally, since 
gonadotropins are composed of two different subunits encoded 
by different genes, changes  in the  synthesis  and secretion of 
the  intact heterodimer may reflect coordinate but independ- 
ent  alterations  in expression of both  the common a subunit 
gene and  the unique @ subunit genes. 
The dynamics of such  a  system are difficult to recapitulate 
in  vitro. This problem is further exacerbated by the lack of 
continuous cell lines that synthesize and secrete biologically 
active LH.  To circumvent these problems, we have utilized a 
transgenic mouse paradigm to study the molecular mecha- 
nisms underlying tissue-specific and hormonally regulated 
expression of the promoter from the gene encoding the com- 
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FIG. 6. Digestion of human a(-170/+45) with RsaI disrupts 
binding of AR. Human CY -170/+45 (fragment 4B) was isolated and 
subjected to RsaI digestion resulting in two fragments, -99/+45 
(fragment 4D) and -170/-99 (fragment 4C). Each  fragment was end- 
labeled with 3zP and used in gel-mobility shift assays with rAR-DBD 
and AR-52 as described in Fig. 5 and under "Experimental Proce- 




FIG. 7. Oligonucleotide competition maps the AR binding 
element to sequences residing between -1201-90 in the hu- 
man (I promoter. Human CY -170/+45 (fragment 4B) was end- 
labeled with '*P and used in  a gel-mobility shift assay with rAR-DBD 
and AR-52 as described under "Experimental Procedures." Four 
separate unlabeled oligonucleotides were added to  the binding reac- 
tions in increasing concentrations as indicated by the wedge. The 
competitor oligonucleotides were added at 12-, 50-, and 100-fold over 
the concentration of probe. A schematic  diagram of the promoter  is 
given at the top of the figure depicting previously characterized 
response elements on the bottom and  the oligonucleotides used in the 
competition above. 
mon a subunit of the glycoprotein hormones. Using this 
transgenic mouse model, we demonstrated previously that 
either 1500 or 315 bp of proximal 5"flanking region derived 
from either  the  human  or b vine a subunit genes are sufficient 
to confer both pituitary-specific and,  in  the case of the  human 
promoter, placenta-specific expression (Bokar et al., 1989). 
Furthermore, it appeared that  pituitary expression of both 
transgenes  is confined to gonadotropes  (Kendall et al., 1991; 
Hamernik et al., 1992), thus validating the use of hormonal 
replacement  paradigms to study regulated expression of the 
transgenes. 
Recently, we have used castration  and steroid  replacement 
experiments  to establish that  both  the  human  and bovine a 
subunit  transgenes  contain sufficient  regulatory  information 
to confer responsiveness to estradiol 17-p and  GnRH,  thus 
paralleling  normal, physiological regulation of the endogenous 
CY subunit gene (Keri et al., 1991; Hamernik et al., 1992). 
Surprisingly, however, we were not able to  demonstrate  the 
presence of a high affinity binding site for ER in the 5'- 
flanking region of the  human CY subunit gene, suggesting that 
negative regulation by estrogen must occur through  an indi- 
rect  mechanism at either  the level of the hypothalamus or  the 
anterior  pituitary  or a combination of the two (Keri et al., 
1991). 
Our present studies not only expand our analysis of the 
regulation of the a subunit promoter in transgenic mice to 
males, where we can  demonstrate  that  both  the human and 
bovine promoters are capable of conferring negative regula- 
tion by androgen, they also suggest fundamentally  different 
mechanisms for androgenic and estrogenic regulation of a 
subunit gene expression. As with the estrogen replacement 
experiments  in females, the  pattern of suppression of expres- 
sion of the a subunit transgenes by androgen mimics the 
normal physiological role of androgen in suppressing tran- 
scription of both  the a and p subunit genes of the gonadotro- 
pins.  Unlike  estrogen, however, some component of the neg- 
ative regulation of a subunit gene expression may be ac- 
counted for by a mechanism involving direct binding of 
activated AR to a negative androgen  response element  (ARE), 
which functions as a negative element  as a  result of its location 
in the proximal  promoter of the a subunit gene. Consistent 
with the known differences in binding  requirements for AR 
and  ER,  this  putative negative ARE cannot bind ER, nor does 
it respond to activated ER in either choriocarcinoma cells 
(Keri et al., 1991) or  pituitary cells (Fig. 4). 
Evidence for a direct effect of  AR on a subunit gene 
expression stems from three basic experimental paradigms: 
1) transgenic mice, 2) transfection  analysis, and  3) gel-mobil- 
ity  shift assays. First, we have shown androgen  suppression 
of both Ha- and BaCAT expression in the pituitaries of 
transgenic mice. Second, co-expression of AR with HaCAT 
in  both BeWo and  aT3 cells leads to  an androgen-dependent 
attenuation of HaCAT expression. Third, we have detected  a 
high affinity, sequence-specific binding site for AR located in 
the proximal  promoter of the Ha subunit gene. Finally, the 
loss of  AR binding  upon digestion of Ha(-170/+45) with RsaI 
implicates the region a t  -101 as  the functional AR binding 
element. As shown in Fig. 8, this region bears homology to a 
consensus GRE/ARE, and, in fact, purified GR has been 
shown to  protect  this region from DNase I digestion (Aker- 
blom et al., 1988). In addition, an analogous region in the 
bovine a promoter also shares homology to the consensus 
GRE/ARE, further  supporting  the notion that  this conserved 
sequence serves as a physiological target for AR. 
The molecular mechanism(s) by which the binding of  AR 
to  the a subunit promoter attenuates  transcription is not yet 
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FIG. 8. Regulatory elements residing within the proximal 
promoter of the human glycoprotein hormone a subunit gene. 
Androgen receptor binds immediately downstream of the tandem 
CRE in the human CY subunit gene promoter. Contained within the 
AR binding region is a  potential GRE (bracketed region) identified 
by Akerblom et al. (1988). Previously defined regulatory elements 
al., 1987; Bokar et al., 1989), JRE (Andersen et al., 1990), CCAAT 
include: upstream regulatory element (URE) and CRE (Delegeane et 
(Kennedy et al., 1990), and a thyroid hormone response element 
(!/',RE) (Chatterjee et  al., 1989). 
clear. At  least four possible mechanisms have been proposed 
for transcriptional repression. These include competition, 
quenching, direct,  and squelching (Levine and Manley, 1989). 
Akerblom et al. (1988) suggested that glucocorticoid suppres- 
sion of human a subunit gene expression could occur by a 
competition mechanism involving binding of GR to a region 
overlapping one of two tandemly repeated CAMP response 
elements in the human a subunit gene promoter. Thus,  the 
binding of GR would presumably block the binding of CREB 
and so diminish expression of the human a subunit gene. 
Although we cannot preclude the possibility of spatial  inter- 
ference of CREB binding by  AR, it would  seem less likely as 
the tandemly repeated CRE  are  not necessary for binding of 
AR. This is indicated by three lines of evidence. First,  the 
ability of AR to bind to Ha(-170/+45) is not compromised 
with the deletion of either one or both of the tandem  CRE 
(data not shown). Second, AR is capable of binding to  the 
proximal 315 bp of 5"flanking region of the bovine a subunit 
gene (data  not shown). This region lacks a  functional  CRE 
(Bokar et al., 1989). Third, oligonucleotide competition with 
the tandem  CRE was not capable of displacing binding of  AR 
to the human a(-170/+45) region (Fig. 7). Thus, the AR 
binding site  and  CREB binding sites do not overlap. 
Instead of co-mapping to  the CRE, the highest affinity AR 
binding site  appears to reside within the  JRE,  another regu- 
latory element located just downstream of the  tandem CRE 
(Andersen et al., 1990) (Fig. 8). The  JRE region has also been 
implicated as binding GR (Akerblom et al., 1988). Thus, it 
appears that  the binding of AR may block binding not of 
CREB,  but of another regulatory protein (JRE transcription 
factor) previously defined as binding to  the  JRE and impor- 
tant for basal expression of the human a subunit gene (An- 
dersen et al., 1990). Targeted  mutation coupled with transfec- 
tion analysis represents the most direct  approach  for  testing 
the functional significance of this AR binding site. Unfortu- 
nately, block mutants  that disrupt AR binding activity also 
disrupt binding of the  JRE transcription factor that  in  turn 
is required for transcriptional activity (Kennedy et al., 1990; 
Andersen et al., 1990). Thus,  a  direct  test of this hypothesis 
awaits the definition of point  mutations that eliminate bind- 
ing of AR to  the a subunit gene while retaining full basal 
transcriptional activity. 
How does androgen attenuate a subunit gene expression in 
vivo? It has long been recognized that testicular androgens 
can  suppress  synthesis and secretion of pituitary gonadotro- 
pins,  in  particular, LH (Desjardins, 1981). Nevertheless, there 
remains considerable question as  to whether the predominant 
site of action of androgen negative feedback occurs at the 
level of the hypothalamus or at the pituitary. Some have 
suggested that  the negative feedback effects of androgen on 
LH synthesis  and secretion in cattle  and sheep occur predom- 
inantly at the level of the hypothalamus (Tilbrook et al., 
1991). In  contrast, in men it appears that androgen effects 
occurring directly at  the level of the pituitary may play an 
important role in regulation of LH synthesis and secretion 
(Finkelstein et al., 1991). The transgenic mouse studies  pre- 
sented herein shed some light on the question of site of action 
of androgen in regard to  the a subunit gene. In contrast to 
our previous work with ER, the presence of a high affinity, 
sequence-specific binding site for AR, located within the 
proximal promoter of the human a subunit gene, provides a 
clear target for AR. In  addition, we have shown that activity 
of the human a subunit promoter can be inhibited in a steroid- 
dependent  manner upon co-expression of  AR in  both  pituitary 
cells and choriocarcinoma cells. Thus,  these  data  point toward 
a direct pituitary site of action for androgen in negative 
regulation of a subunit gene expression. Clearly, a  pituitary 
site of action does not preclude a hypothalamic site of action 
for androgen as well. In fact, full negative regulation of a 
subunit gene expression by androgen likely involves a com- 
bination of the two. The construction of transgenic mice 
harboring mutant a subunit promoters that retain full tran- 
scriptional activity but do not bind AR should provide a 
powerful approach for assessing the relative contribution of 
hypothalamic and pituitary sites of action of androgen in 
suppressing transcription of the a subunit gene. 
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